In the first part of this final exam, you will use a hypothetical dataset Anti-inflammation drug and Covid-19 trial data Wi21 FE.xlex', comparing the effectiveness of three anti-inflammation drugs/treatments in helping patients recover from Covid-19 (ie., how long it takes to recover and be discharged from the hospital). Recovery is operationalized as length of stay in the hospital or number of days to be discharged from the hospital. In other words, we want to see which of these three drugs/treatments help patients recover fastest from Covid-19 using length of hospital stay as a proxy. (As we witnessed over the past year or so, hospitals are overwhelmed with Covid-19 patients and speedy recovery is critical.) The independent predictor variable is the Treatment with three randomly assigned group of Covid-19 patients: Group #1 received the standard treatment that includes the drug Dexamethasone, Group #2 received treatment that includes the new drug Tocilizumab, Group #3 received treatment that includes the new drug Sarilumab. The dependent/outcome variable is recovery time, i.e., the number of days to be discharged from the hospital. This dataset includes three additional variables that may make difference in recovery time regardless of drug treatment they are receiving: 1. Age (Age) 2. Sex (Sex) (1=Female, 2=Male) 3. Race/Ethnicity (1=Asian, 2=American Indian/Alaskan Native, 3=Black/African American, 4=Hispanic, 5=Native Hawaiian, 6=White, 7=Mixed race)